{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:16:55Z","timestamp":1788243415740,"version":"build-2803163510"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Frequent intravitreal administration of antivascular endothelial growth factor Vascular endothelial growth factor agents remains a major limitation in the management of wet age-related macular degeneration (wAMD). This study evaluated whether suprachoroidal delivery of an engineered recombinant adeno-associated viral (rAAV)-aflibercept vector could achieve sustained, targeted expression with improved efficacy and safety compared with intravitreal administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>AL-001, an engineered rAAV vector expressing aflibercept, was developed and characterized. Its expression profile was first assessed in New Zealand white rabbits following suprachoroidal space (SCS) injection. Efficacy, pharmacokinetics, and safety were then evaluated in a nonhuman primate model of laser-induced choroidal neovascularization (CNV), comparing SCS and intravitreal (IVT) administration routes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      AL-001 efficiently expressed aflibercept in relevant ocular cells\n                      <jats:italic>in vitro<\/jats:italic>\n                      . In rabbits, SCS administration produced sustained aflibercept levels in ocular tissues. In the nonhuman primate CNV model, a single SCS injection of AL-001 showed favorable efficacy to IVT injection and a notable mild inflammatory response. At week 4, grade IV lesion incidence was 0% (0\/48) after SCS administration versus 14.3% (6\/42) after IVT administration (absolute difference, \u221214.3 percentage points; 95% CI, 3.7%\u201327.8%;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.0258). Throughout follow-up, mean leakage area and grade IV lesion incidence remained 0 with SCS, versus IVT peaks of approximately 0.3\u00a0mm\n                      <jats:sup>2<\/jats:sup>\n                      and 33.0%, respectively, declining to 0.03\u00a0mm\n                      <jats:sup>2<\/jats:sup>\n                      and 2.0% by day 100. Both the medium and high doses decreased pathological vascular leakage and subretinal hyperreflective material. Vector administration preceded laser-induced CNV modeling, demonstrating that sustained intraocular aflibercept expression in the retina and choroid provided durable antiangiogenic protection. Pharmacokinetic analysis confirmed distinct ocular exposure profiles between routes, with viral genomes confined predominantly to the injected eye and no significant systemic accumulation. AL-001 was well tolerated, without sustained intraocular pressure elevation or severe ocular inflammation, and only mild-to-moderate treatment-emergent adverse events. Low pre-existing anti-AAV2 immunity and time-dependent neutralizing antibody responses postdosing, informing a translational model for patient stratification and redosing feasibility.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Suprachoroidal administration of AL-001 is well tolerated and provides durable, targeted aflibercept expression with pronounced antiangiogenic efficacy. These results support AL-001 as a promising, long-acting therapeutic candidate for wAMD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fgene.2026.1836684","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:10:12Z","timestamp":1788243012000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical evaluation of AL-001, a gene therapy for wet age-related macular degeneration"],"prefix":"10.3389","volume":"17","author":[{"given":"Xuan","family":"Liu","sequence":"first","affiliation":[{"name":"Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University","place":["Changping, Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Liu","sequence":"additional","affiliation":[{"name":"GCP ClinPlus Co., Ltd.","place":["Fengtai, Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[{"name":"Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University","place":["Changping, Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Zhao","sequence":"additional","affiliation":[{"name":"Anlongbio Inc., Zhongguancun Medical Engineering and Health Industrialization Base","place":["Shunyi, Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingwang","family":"Xie","sequence":"additional","affiliation":[{"name":"Beijing CorreGene Biotechnology Co., Ltd, Chang Development Precision Medicine Acceleration Center","place":["Haidian, Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Jiang","sequence":"additional","affiliation":[{"name":"GCP ClinPlus Co., Ltd.","place":["Fengtai, Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlin Adam","family":"Zhao","sequence":"additional","affiliation":[{"name":"Anlongbio Inc., Zhongguancun Medical Engineering and Health Industrialization Base","place":["Shunyi, Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMcp2102061","article-title":"Age-Related macular degeneration","volume":"385","author":"Apte","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1038\/s41433-024-03308-6","article-title":"Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era","volume":"38","author":"Armendariz","year":"2024","journal-title":"Eye (Lond)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.3390\/bioengineering12101072","article-title":"Gene therapy for wet age-related macular degeneration","volume":"12","author":"Barthelemy","year":"2025","journal-title":"Bioeng. (Basel)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e002334","DOI":"10.1136\/bmjophth-2025-002334","article-title":"Tracking real-world persistence and adherence to anti-VEGF intravitreal therapy with prefilled syringes: a German prescription sales analysis","volume":"10","author":"Brunner","year":"2025","journal-title":"BMJ Open Ophthalmol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.3390\/ijms21124197","article-title":"Recombinant adeno-associated viral vectors (rAAV)-Vector elements in ocular gene therapy clinical trials and transgene expression and bioactivity assays","volume":"21","author":"Buck","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(24)00310-6","article-title":"Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1\/2a dose-escalation study","volume":"403","author":"Campochiaro","year":"2024","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12886-021-02055-6","article-title":"Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study","volume":"21","author":"Corazza","year":"2021","journal-title":"BMC Ophthalmol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e02440-20","DOI":"10.1128\/JVI.02440-20","article-title":"Effects of altering HSPG binding and capsid hydrophilicity on retinal transduction by AAV","volume":"95","author":"Crosson","year":"2021","journal-title":"J. Virol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1167\/iovs.63.9.11","article-title":"Animal models of choroidal neovascularization: a systematic review","volume":"63","author":"Fabian-Jessing","year":"2022","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.3390\/cells11121881","article-title":"Immunogenicity of novel AAV capsids for retinal gene therapy","volume":"11","author":"Gehrke","year":"2022","journal-title":"Cells"},{"key":"B11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1089\/jop.2021.0001","article-title":"Comprehensive preclinical assessment of ADVM-022, an intravitreal Anti-VEGF gene therapy for the treatment of neovascular AMD and diabetic macular edema","volume":"37","author":"Gelfman","year":"2021","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e0132643","DOI":"10.1371\/journal.pone.0132643","article-title":"Optimization of an image-guided laser-induced choroidal neovascularization model in mice","volume":"10","author":"Gong","year":"2015","journal-title":"PLoS One"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.3390\/ph16081140","article-title":"Intravitreal anti-vascular endothelial growth factor therapies for retinal disorders","volume":"16","author":"Hang","year":"2023","journal-title":"Pharm. (Basel)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1208\/s12248-023-00880-9","article-title":"Recommendations for method development and validation of qPCR and dPCR assays in support of cell and gene therapy drug development","volume":"26","author":"Hays","year":"2024","journal-title":"Aaps J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1089\/jop.2019.0126","article-title":"Suprachoroidal delivery of viral and nonviral gene therapy for retinal diseases","volume":"36","author":"Kansara","year":"2020","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1148795","DOI":"10.3389\/fddev.2023.1148795","article-title":"AAV2 and AAV9 tropism and transgene expression in the mouse eye and major tissues after intravitreal and subretinal delivery","volume":"3","author":"Koponen","year":"2023","journal-title":"Front. Drug Deliv."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2222545","DOI":"10.1080\/07853890.2023.2222545","article-title":"Incidence and prevalence of neovascular age-related macular degeneration: 15-year epidemiological study in a population-based cohort in Finland","volume":"55","author":"Korva-Gurung","year":"2023","journal-title":"Ann. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/nprot.2013.135","article-title":"Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice","volume":"8","author":"Lambert","year":"2013","journal-title":"Nat. Protoc."},{"key":"B19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3892\/etm.2025.12893","article-title":"Advances in the molecular signaling mechanisms of VEGF\/VEGFR2 in fundus neovascularization disease","volume":"30","author":"Li","year":"2025","journal-title":"Exp. Ther. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"112265","DOI":"10.1016\/j.isci.2025.112265","article-title":"The clinical safety landscape for ocular AAV gene therapies: a systematic review and meta-analysis","volume":"28","author":"Liu","year":"2025","journal-title":"iScience"},{"key":"B21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s40942-025-00740-y","article-title":"Aflibercept, ranibizumab, and bevacizumab for macular neovascularization secondary to age-related macular degeneration: a retrospective OCT-angiography study","volume":"11","author":"Lombardo","year":"2025","journal-title":"Int. J. Retina Vitr."},{"key":"B22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/IIO.0000000000000366","article-title":"Ocular inflammation and treatment emergent adverse events in retinal gene therapy","volume":"61","author":"Mehta","year":"2021","journal-title":"Int. Ophthalmol. Clin."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","article-title":"Age-related macular degeneration","volume":"392","author":"Mitchell","year":"2018","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41434-022-00380-z","article-title":"Improving adeno-associated viral (AAV) vector-mediated transgene expression in retinal ganglion cells: comparison of five promoters","volume":"30","author":"Nieuwenhuis","year":"2023","journal-title":"Gene Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1089\/hum.2024.079","article-title":"Prevalence of neutralizing antibodies against AAV serotypes 2 and 9 in healthy participants from multiple centers across China and patients with DMD\/BMD","volume":"35","author":"Qin","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"720","DOI":"10.3390\/genes15060720","article-title":"Gene therapy for non-hereditary retinal disease: age-related macular degeneration, diabetic retinopathy, and beyond","volume":"15","author":"Rowe","year":"2024","journal-title":"Genes"},{"key":"B28","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1186\/s12886-023-03214-7","article-title":"Comparative efficacy of aflibercept and ranibizumab in the treatment of age-related macular degeneration with retinal pigment epithelial detachment: a systematic review and network meta-analysis","volume":"23","author":"Sun","year":"2023","journal-title":"BMC Ophthalmol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"116902","DOI":"10.1016\/j.bcp.2025.116902","article-title":"Advancements in age-related macular degeneration treatment: from traditional anti-VEGF to emerging therapies in gene, stem cell, and nanotechnology","volume":"236","author":"Wang","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41434-023-00409-x","article-title":"Immunobiology of a rationally-designed AAV2 capsid following intravitreal delivery in mice","volume":"30","author":"Whitehead","year":"2023","journal-title":"Gene Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob. Health"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3390\/ph16091241","article-title":"Suprachoroidal injection: a novel approach for targeted drug delivery","volume":"16","author":"Wu","year":"2023","journal-title":"Pharm. (Basel)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.omtm.2022.07.018","article-title":"Immunogenicity assessment of AAV-Based gene therapies: an IQ consortium industry white paper","volume":"26","author":"Yang","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.2147\/opth.s461846","article-title":"Factors involved in Anti-VEGF treatment decisions for neovascular age-related macular degeneration: insights from real-world clinical practice","volume":"18","author":"Yiu","year":"2024","journal-title":"Clin. Ophthalmol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1186\/s12889-024-21047-x","article-title":"Global burden of low vision and blindness due to age-related macular degeneration from 1990 to 2021 and projections for 2050","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Public Health"}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2026.1836684\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:10:13Z","timestamp":1788243013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2026.1836684\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":35,"alternative-id":["10.3389\/fgene.2026.1836684"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2026.1836684","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"1836684"}}